Gilles Gallant

Gilles Gallant

Company: Daiichi Sankyo

Job title: SVP Global Head, Oncology Department, Oncology R&D


Development of ENHERTU, An HER2-directed Dxd ADC, In Early Breast Cancer & Beyond 8:30 am

Discussing Destiny-Breast03, a Phase 3 randomised study of ENHERTU versus T-DM1 in patients with HER2+ metastatic breast cancer Reviewing plans to develop ENHERTU in early breast cancer Describing plans to expand the development of ENHERTU in gastric cancer, NSCLC and other tumoursRead more

day: Day Two

Showcasing the Development of DS-7300, a B7-H3-Directed DXd Antibody-Drug Conjugate 2:15 pm

• Evaluating the pre-clinical profile and mechanism of action of DS-7300 • Sharing the clinical development status of DS-7300 • Discussing future developments of DS- 7300Read more

day: Track C - Day 1 - PM

Industry Leaders Panel Discussion – Reviewing the Last Year & Creating Strategies to Further Develop ADCs Through 2022 9:30 am

Reviewing how breakthroughs in 2021 are shaping the ADC industry What decision are industry pioneers making to ensure continued progress within the ADC space (technical and business/partnership decisions)? Outlining the biggest challenges that ADC drug developers are facing in taking drugs from the bench to bedside Discussing methods to bring ADCs to earlier-line treatmentRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.